Clinical trial
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous…
NCT03665597 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT03665597 |
|---|---|
| Title | Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) |
| Official title | A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B, Pembrolizumab Dose D |
| Enrollment | 138 |
| Start date | Nov 19, 2018 |
| Primary completion | Dec 4, 2023 |
| Completion | Dec 4, 2023 |
| First posted | Sep 11, 2018 |
| Last update posted | Feb 10, 2025 |
| Countries | Australia, South Africa, Spain, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: